Back to search results

Understanding Immune Cells After Transplant for Graft-Versus-Host Disease

This observational study aims to understand why some people develop chronic graft-versus-host disease (cGVHD) after an allogeneic hematopoietic cell transplant (a stem cell transplant using donor cells). Researchers will look at immune cells, specifically T cells, B cells, and macrophages, in your blood over two years. You can join if you've had an allogeneic hematopoietic cell transplant, regardless of your donor type or treatment plan. The study hopes to identify factors that contribute to cGVHD by comparing immune cells in people who do and do not develop the condition. There are 75 planned participants, but the current recruitment status is unclear.

Study design
This is an observational study with 75 planned participants. It is not testing a new treatment but rather observing patients in two groups.
What's involved
Depending on your group, you would provide blood, saliva/buccal (cheek swab), and stool samples once or multiple times over up to two years. Your medical records will also be reviewed.
Compensation
Not stated in the trial record.
Follow-up
You would be followed for up to two years, which is when the study is completed.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT07235501

Kinetic Analysis of Immune Cells in Blood and Chronic Graft-Versus-Host Disease-Affected Tissues After Allogeneic Hematopoietic Cell Transplantation

Not Yet Recruiting
Not specifiedAges 7+Observational
City of Hope Medical Center
~75 participants
Updated 2026-08-27 on ClinicalTrials.gov
What's tested:Non-Interventional Study

At a glance

Recruiting sites
0 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
T cell measurements
Measured over Up to 2 years - study completion
+2 more outcomes measured

Conditions

Graft Versus Host Disease
Hematopoietic and Lymphatic System Neoplasm
Malignant Solid Neoplasm

Explore related trials

Graft Versus Host DiseaseHematopoietic and Lymphatic System NeoplasmMalignant Solid Neoplasm

Where it's being run

1 sites across 1 states
California1

Study leadership

  • Ryotaro Nakamura · PRINCIPAL_INVESTIGATOR · City of Hope Medical Center

Who to contact

Ryotaro Nakamura
[email protected]
626-218-2405
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

\* BOTH COHORTS:
Documented written informed consent of the participant and/or parent/guardian.
Assent from pediatric participants will be documented per institutional policies and practice.
Patients who have received allogeneic hematopoietic cell transplant (HCT) regardless of donor type, condition regimen, or GVHD prophylaxis.
Age: ≥ 18 years or ≥ 7 years if 30 kg and above
Willingness to:
Provide blood sample(s), stool, saliva, and buccal mucosa,
If applicable: Permit medical record/ clinical laboratory result review
COHORT 1:
Patients who have received allogeneic hematopoietic cell transplant (HCT) regardless of donor type, condition regimen, or GVHD prophylaxis.
COHORT 2:
Patients diagnosed with cGVHD at any time-point after allogeneic HCT regardless of donor type, condition regimen, or GVHD prophylaxis.

Exclusion

\* Women of childbearing potential: Pregnant/nursing
Individuals with impaired decision-making capacity
An employee who is under the direct/ indirect supervision of the PI/ a co-investigator/ the study manager
A direct study team member

What this trial measures

  • T cell measurementsUp to 2 years - study completion

    Defined as percentage of naïve and memory T cells using high dimensional flow cytometry.

  • B cell measurementsUp to 2 years - study completion

    Defined as percentage of naïve B, memory B, and plasma cells using high dimensional flow cytometry.

  • Macrophage measurementsUp to 2 years - study completion

    Defined as percentage of M1, M2, and M0 using high dimensional flow cytometry.